Pharminox

Pharminox is a drug discovery company focused on the development of novel small molecule therapies for the treatment of cancer. Based in the United Kingdom, the company was established as a spin-out from the University of Nottingham by the research team responsible for the discovery of temozolomide, a standard-of-care treatment for glioblastoma. Pharminox specializes in targeting DNA structures and the tumor microenvironment, with a particular emphasis on G-quadruplex stabilizers and hypoxia-activated prodrugs. The company's research aims to address unmet needs in oncology by creating compounds that can bypass common resistance mechanisms. Pharminox operates primarily through a virtual model, collaborating with academic and industrial partners to advance its pipeline. Its lead programs are currently in the pre-clinical stage of development.